Paper39695697
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
Hose D and 25 others. J Hematol Oncol, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma. Papers, record 39695697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39695697
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Bortezomib | Major topic |
| Silicon Dioxide | Major topic |
| Collagen | Major topic |
| Neoplasm, Residual | Major topic |
| Animals | |
| Rats | |
| Mice | |
| Humans | |
| Osteolysis | |
| Antineoplastic Agents | |
| Gels | |
| Male | |
| Cell Line, Tumor |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| SFB/TRR79 | Deutsche Forschungsgemeinschaft | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 39856743 | Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma. | https://conductscience.org/library/papers/39856743 |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 368243 | Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. | J Immunol | 1979 | https://conductscience.org/library/papers/368243 | PubMed |
| 2 | 25477008 | Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. | Cancer Chemother Pharmacol | 2015 | https://conductscience.org/library/papers/25477008 | PubMed |
| 3 | 17910634 | Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. | Br J Haematol | 2007 | https://conductscience.org/library/papers/17910634 | PubMed |
| 4 | 27497232 | Nanocrystallinity effects on osteoblast and osteoclast response to silicon substituted hydroxyapatite. | J Colloid Interface Sci | 2016 | https://conductscience.org/library/papers/27497232 | PubMed |
| 5 | 39119424 | Chemotherapy Release From Bortezomib-Impregnated Polymethylmethacrylate-Coated Intramedullary Nails: A Novel In Vitro Study for a Local Chemotherapy Delivery Device. | Cureus | 2024 | https://conductscience.org/library/papers/39119424 | PubMed |
| 6 | 15461798 | Bioconductor: open software development for computational biology and bioinformatics. | Genome Biol | 2004 | https://conductscience.org/library/papers/15461798 | PubMed |
| 7 | 33284948 | A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. | Blood Adv | 2020 | https://conductscience.org/library/papers/33284948 | PubMed |
| 8 | 20533309 | Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. | J Bone Miner Res | 2010 | https://conductscience.org/library/papers/20533309 | PubMed |
| 9 | 30606515 | Effects of MgO, ZnO, SrO, and SiO2 in tricalcium phosphate scaffolds on in vitro gene expression and in vivo osteogenesis. | Mater Sci Eng C Mater Biol Appl | 2019 | https://conductscience.org/library/papers/30606515 | PubMed |
| 10 | 30079070 | CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. | Front Immunol | 2018 | https://conductscience.org/library/papers/30079070 | PubMed |
| 11 | 19281987 | Quantitative measures of femoral fracture repair in rats derived by micro-computed tomography. | J Biomech | 2009 | https://conductscience.org/library/papers/19281987 | PubMed |
| 12 | 17371942 | The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. | Blood | 2007 | https://conductscience.org/library/papers/17371942 | PubMed |
| 13 | 25293776 | Curing myeloma at last: defining criteria and providing the evidence. | Blood | 2014 | https://conductscience.org/library/papers/25293776 | PubMed |
| 14 | 9275021 | Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. | Br J Cancer | 1997 | https://conductscience.org/library/papers/9275021 | PubMed |
| 15 | 19196662 | Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. | Blood | 2009 | https://conductscience.org/library/papers/19196662 | PubMed |
| 16 | 25680544 | Bioactive silica nanoparticles reverse age-associated bone loss in mice. | Nanomedicine | 2015 | https://conductscience.org/library/papers/25680544 | PubMed |
| 17 | 31242924 | Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31242924 | PubMed |
| 18 | 12528874 | Review of 1027 patients with newly diagnosed multiple myeloma. | Mayo Clin Proc | 2003 | https://conductscience.org/library/papers/12528874 | PubMed |
| 19 | 28686535 | Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28686535 | PubMed |
| 20 | 19345651 | Bioactive silica-collagen composite xerogels modified by calcium phosphate phases with adjustable mechanical properties for bone replacement. | Acta Biomater | 2009 | https://conductscience.org/library/papers/19345651 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41471085 | Plasma Cell Myeloma: Biochemical Insights into Diagnosis, Treatment, and Smart Nanocarrier-Based Therapeutic Development. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41471085 | PubMed |
| 41188965 | Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening. | J Biol Eng | 2025 | https://conductscience.org/library/papers/41188965 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39695697
GET https://conductscience.org/api/papers/v1/39695697/authors?page=2